Our research may suggest a possible therapeutic use of PD‐1/PD‐L1 inhibition in Zollinger Ellison syndrome patients with either primary gastrinomas or other gastrin‐producing tumors.57, 58. This evidence concerns the gene CD274 and Zollinger-Ellison syndrome.